title: Quantitative Systems Pharmacology: A Case for Disease Models.
abstract: Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
authors.affiliation: Pfizer Inc, Cambridge, Massachusetts, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Musante
authors.affiliation: Genentech, South San Francisco, California, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ramanujan
authors.affiliation: Bristol-Myers Squibb, Princeton, New Jersey, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Schmidt
authors.affiliation: No institutional affiliation at the time of this research.
authors.forename: O G
authors.initials: OG
authors.lastname: Ghobrial
authors.affiliation: AstraZeneca, Cambridge, UK.
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.affiliation: Pfizer Inc, Cambridge, Massachusetts, USA.
authors.forename: A C
authors.initials: AC
authors.lastname: Heatherington
mesh_terms: D035843:Biomedical Research / Q000379:methods; D002986:Clinical Trials as Topic / Q000379:methods; D003657:Decision Making; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D010601:Pharmacology, Clinical / Q000379:methods; D049490:Systems Biology / Q000379:methods*